lipolysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-05 and is reviewed periodically as new material appears.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
== History == Vicine was initially isolated in 1870 from the seeds of Vicia sativa by a method of extraction with sulfuric acid and subsequent precipitation with mercury sulfate (HgSO4). Later vicine was also found in other Vicia species, namely Vicia faba, beet juice and peas. The chemical structure of the compound was built gradually. First the glycosidic nature of the compound was recognized in 1896. The same year the aglycone of vicine, divicine, was isolated. In the beginning of the 20th century the pyrimidine structure was recognized. Despite these initial successes, the correct formula of vicine was determined only in 1953 and it is 2,4-diamino-6-oxypyrimidine-5-(β-D-glucopyranoside).
=== Geometry === The majority of β-strands are arranged adjacent to other strands and form an extensive hydrogen bond network with their neighbors in which the N−H groups in the backbone of one strand establish hydrogen bonds with the C=O groups in the backbone of the adjacent strands. In the fully extended β-strand, successive side chains point straight up and straight down in an alternating pattern. Adjacent β-strands in a β-sheet are aligned so that their Cα atoms are adjacent and their side chains point in the same direction. The "pleated" appearance of β-strands arises from tetrahedral chemical bonding at the Cα atom; for example, if a side chain points straight up, then the bonds to the C′ must point slightly downwards, since its bond angle is approximately 109.5°. The pleating causes the distance between Cαi and Cαi + 2 to be approximately 6 Å (0.60 nm), rather than the 7.6 Å (0.76 nm) expected from two fully extended trans peptides. The "sideways" distance between adjacent Cα atoms in hydrogen-bonded β-strands is roughly 5 Å (0.50 nm).
== Origin/development == The sulcular epithelium originates developmentally during tooth eruption when the reduced enamel epithelium derived from the enamel organ fuses with the oral epithelium to form a continuous epithelial lining around the tooth. The junctional epithelium is attached coronally to the sulcular epithelium which is thicker. At the bottom of the sulcus is the junctional epithelium in which the development starts with the reduced enamel epithelium the protective layer of epithelial tissue that covers the enamel before the eruption of the tooth forming a seal.The rest of the part separating the junctional epithelium with the oral epithelium at the free gingival margin is covered by the sulcular epithelium. Gingival epithelium complex covers the alveolar bone to the neck of the tooth and the sulcular epithelium is a component or part of this complex which helps in the preservation of periodontal health. The sulcular epithelium is described as stratified but non-keratinized unlike the attached gingival epithelium which is keratinized.The sulcular epithelium expresses a characteristic cytokeratin pattern in particular keratins K4 and K13.
The Cherokee Nation (Cherokee: ᏣᎳᎩᎯ ᎠᏰᎵ, romanized: Tsalagihi Ayeli or ᏣᎳᎩᏰᎵ, Tsalagiyehli) is the largest of three federally recognized Cherokee tribes in the United States. Headquartered in Tahlequah, Oklahoma, the nation had 477,673 enrolled citizens as of 2026 (including 289,619 living in Oklahoma), making it one of the largest tribal nations in the country. The tribe includes people descended from members of the Old Cherokee Nation who relocated, due to increasing pressure, from the Southeast to Indian Territory and Cherokee who were forced to relocate on the Trail of Tears. The tribe also includes descendants of Cherokee Freedmen and the Natchez Nation. The nation operates under a constitution ratified in 2003, with executive, legislative, and judicial branches. In 2020 and 2021, federal and state courts affirmed that the Cherokee Nation's reservation—spanning 14 counties in northeastern Oklahoma—was never disestablished, restoring reservation status under the McGirt v. Oklahoma precedent. The nation has jurisdiction within this territory. The nation publishes the Cherokee Phoenix, the first Native American newspaper, and operates Cherokee language immersion schools. The Cherokee Nation has a reservation spanning 14 counties in the northeastern corner of Oklahoma. These are Adair, Cherokee, Craig, Delaware, Mayes, McIntosh, Muskogee, Nowata, Ottawa, Rogers, Sequoyah, Tulsa, Wagoner, and Washington counties.
=== Computing === Hyperlink, from one electronic document to another link (Unix), a command-line program to link directory entries <link>, a type of HTML element Link, in a linked list Linker (computing), a program which converts object files to an executable Links (web browser) Microsoft Office Assistant Links, an animated cat Link layer in computer networking ln (Unix), a command-line program to create a link to a file Chainlink (blockchain), a cryptocurrency Link, an Internet wallet service from Stripe, Inc.
Sources: en.wikipedia.org
=== Digestive system === Somatostatin is secreted by delta cells at several locations in the digestive system, namely the pyloric antrum, the duodenum and the pancreatic islets. Somatostatin released in the pyloric antrum travels via the portal venous system to the heart, then enters the systemic circulation to reach the locations where it will exert its inhibitory effects. In addition, somatostatin release from delta cells can act in a paracrine manner. In the stomach, somatostatin acts directly on the acid-producing parietal cells via a G-protein coupled receptor (which inhibits adenylate cyclase, thus effectively antagonising the stimulatory effect of histamine) to reduce acid secretion. Somatostatin can also indirectly decrease stomach acid production by preventing the release of other hormones, including gastrin and histamine which effectively slows down the digestive process.
=== Circulatory system === Arenobufagin works like cardiac glycosides. It inhibits the sodium-potassium pump because it stabilises the E2-P transition state, in which the pump is inactive. Second membrane transporter NCX is responsible for 3Na/Ca transport, if the Na-K-Pump does not function correctly the Ca concentration inside the cell will rise and this will cause heart failure. However, in experiments concerning the anti-cancer effects of arenobufagin in mice, no negative effects where found.
Even moderate sustained use of alcohol may increase anxiety and depression levels in some individuals. In most cases these drug induced psychiatric disorders fade away with prolonged abstinence. A protracted withdrawal syndrome can also occur with psychiatric and other symptoms persisting for months after cessation of use. Among the currently prevalent medications, benzodiazepines are the most notable drug for inducing prolonged withdrawal effects with symptoms sometimes persisting for years after cessation of use. Prospective epidemiological studies do not support the hypotheses that comorbidity of substance use disorders with other psychiatric illnesses is primarily a consequence of substance use or dependence or that increasing comorbidity is largely attributable to increasing use of substances. Yet emphasis is often on the effects of substances on the brain creating the impression that dual disorders are a natural consequence of these substances. However, addictive drugs or exposure to gambling will not lead to addictive behaviors or drug dependence in most individuals but only in vulnerable ones, although, according to some researchers, neuroadaptation or regulation of neuronal plasticity, and molecular changes, may alter gene expression in some cases and subsequently lead to substance use disorders. Research instruments are also often insufficiently sensitive to discriminate between independent, true dual pathology, and substance-induced symptoms.
2 H2O2 → 2 H2O + O2 The rate of decomposition increases with rise in temperature, concentration, and pH. H2O2 is unstable under alkaline conditions. Decomposition is catalysed by various redox-active ions or compounds, including most transition metals and their compounds (e.g. manganese dioxide (MnO2), silver, and platinum).
Balmer Lawrie & Co. Ltd. (BL) is an Indian central public sector undertaking and a conglomerate under the Ministry of Petroleum and Natural Gas, Government of India. It is classified as a category-I Miniratna company. Originally founded in 1867 by George Stephen Balmer and Alexander Lawrie in Calcutta, British India, the conglomerate has eight strategic business units, four joint ventures in India and abroad, and a subsidiary in India.
Sources: en.wikipedia.org
== Background == This was the first of the new President Trump's executive orders and was a mass undoing of the previous president's policies on a wide range of issues. Its core effect was the rescinding of several executive orders ordered by President Biden. It was followed that day by 25 other executive orders covering a wide range of policies and was signed in an open to the public event with attendance by Vice President JD Vance.
== Metabolism == The bacteria rely on the enzyme glycerol-3-phosphate dehydrogenase (GPDH). GPDH is an alternative when managing electrons that are produced during metabolism. In the absence of the electron transport chain, T. pallidum uses GPDH to recycle the NAD+ by oxidizing glycerol-3-phosphate to dihydroxyacetone phosphate and make NAD+ to keep glycolysis and other redox-dependent energy reactions. By doing this, it helps balance the ATP yield without weighing down the protein's limited supply for essential tasks. T. pallidum uses an enzyme called pyrophosphate-dependent phosphofructokinase rather than ATP as a way to save energy and optimize its limited resources. T. pallidum manages without a complete tricarboxylic acid cycle and oxidative phosphorylation by using different efficient strategies including redox balancing and substrate-level to survive the nutrient-limited host environment. T. pallidum lacks enzyme orthologs for superoxide dismutase, however it does possess a superoxide reductase, maintaining the ability to reduce reactive oxygen species. In addition, T. pallidum encodes an alkyl hydroperoxide reductase C, which allows for the reduction of hydrogen peroxide to water and alcohols. This enzyme relies on TP0919, a protein present in the cytoplasm of T. pallidum. T.pallidum primarily relies on glucose as its primary carbon source through glycolysis, but one study has proposed the bacterium uses an acetogenic-energy conservation pathway as a way to catabolize D-lactate as an alternative carbon source.
=== Combinatorial library synthesis === Robotics have applications with combinatorial chemistry which has great impact on the pharmaceutical industry. The use of robotics has allowed for the use of much smaller reagent quantities and mass expansion of chemical libraries. The "parallel synthesis" method can be improved upon with automation. The main disadvantage to "parallel-synthesis" is the amount of time it takes to develop a library, automation is typically applied to make this process more efficient. The main types of automation are classified by the type of solid-phase substrates, the methods for adding and removing reagents, and design of reaction chambers. Polymer resins may be used as a substrate for solid-phase. It is not a true combinatorial method in the sense that "split-mix" where a peptide compound is split into different groups and reacted with different compounds. This is then mixed back together split into more groups and each groups is reacted with a different compound. Instead the "parallel-synthesis" method does not mix, but reacts different groups of the same peptide with different compounds and allows for the identification of the individual compound on each solid support. A popular method implemented is the reaction block system due to its relative low cost and higher output of new compounds compared to other "parallel-synthesis" methods. Parallel-Synthesis was developed by Mario Geysen and his colleagues and is not a true type of combinatorial synthesis, but can be incorporated into a combinatorial synthesis.
=== Misuse potential === Baclofen can produce a feeling of well-being, relaxation, and mild euphoria. Baclofen, at standard dosing, does not appear to possess addictive properties, and has not been associated with any degree of drug craving.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.